Filing Analysis
Co-Diagnostics, Inc. announced its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Report date: August 13, 2026
- The filing includes a press release (Exhibit 99.1) containing financial results and non-GAAP measures.
- Signed by Brian Brown, Chief Financial Officer.
Co-Diagnostics, Inc. entered into an inducement agreement to have existing warrant holders exercise warrants for cash in exchange for the issuance of new warrants. This transaction is expected to raise approximately $2.67 million but will result in significant dilution through the issuance of up to 3,404,724 new warrant shares.
🚩 Red Flags
- Significant Dilution: The issuance of new warrants represents a massive increase in the potential share count (approx. 31% increase in total outstanding shares upon exercise).
- Warrant Inducement: Using new warrants to induce the exercise of old ones is often a sign of liquidity pressure.
- Nasdaq Compliance: The need for stockholder approval for the new warrants suggests complexity in maintaining Nasdaq listing requirements or compliance with structural rules.
📋 Key Facts
- Existing Warrants: 1,702,362 shares at an exercise price of $1.571 per share.
- New Warrants: Up to 3,404,724 shares at an exercise price of $1.56 per share.
- Expected gross proceeds from existing warrant exercise: ~$2.67 million.
- Placement Agent: Maxim Group LLC (7.0% cash fee + $50,000 expense reimbursement).
- Share Count Impact: Outstanding shares expected to increase from 5,277,846 to 6,980,208 post-closing.
- Closing Date: Expected on or about August 3, 2026.
- Requirement: New warrants require stockholder approval per Nasdaq rules.
Co-Diagnostics, Inc. has amended its existing equity distribution agreement with Maxim Group LLC to remove the fixed aggregate dollar limitation on stock sales. This allows for unlimited future issuances of common stock up to the amount currently available in the company's effective registration statement.
🚩 Red Flags
- Removal of dollar caps on equity distribution increases the potential for significant shareholder dilution.
- The extension of a 'no-issuance' period suggests ongoing negotiations or restrictions regarding capital raising with existing investors.
📋 Key Facts
- Amendment to Original Equity Distribution Agreement dated July 27, 2026.
- Removal of fixed aggregate dollar limitation on sales under the agreement.
- Future sales will be limited only by the amount of Common Stock available in the effective registration statement (Shelf Registration No. 333-295803).
- The company agreed to extend a 'no-issuance' period with investors from May 19, 2026, agreements until August 14, 2026.
Co-Diagnostics, Inc. has approved a 1-for-30 reverse stock split to be effective at 11:59 pm MT on January 1, 2026. The split aims to consolidate shares and will result in approximately 2,095,031 shares of common stock outstanding.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq minimum bid price requirements or avoid delisting).
- Significant reduction in share count/liquidity profile.
📋 Key Facts
- Reverse stock split ratio is set at 1-for-30.
- Effective date: January 1, 2026, at 11:59 pm Mountain Time.
- Trading on a split-adjusted basis commences January 2, 2026, on the Nasdaq Capital Market.
- Every 30 shares of common stock will be converted into one share; fractional shares will be rounded up to the next whole number.
- New CUSIP number: 189763204.
- Post-split outstanding shares: approximately 2,095,031.
Co-Diagnostics, Inc. held a special meeting of shareholders on December 5, 2025, where shareholders approved an amendment to the Articles of Incorporation to authorize a reverse stock split.
🚩 Red Flags
- Reverse stock split authorization (often used to maintain Nasdaq listing compliance or improve share price)
- High number of 'Against' votes relative to total shares cast (approx. 13.5% opposition)
📋 Key Facts
- Special meeting held on December 5, 2025.
- Shareholders approved a reverse stock split ratio between 1-for-2 and 1-for-30.
- The Board of Directors is authorized to determine the final ratio within a twelve-month period without further shareholder approval.
- Voting results: 26,465,960 For; 4,213,378 Against; 194,746 Abstain.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing includes a press release containing non-GAAP financial measures.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The company issued a press release (Exhibit 99.1) regarding financial results.
- Financial results include the use of non-GAAP financial measures.
Co-Diagnostics, Inc. entered into a securities purchase agreement for a registered direct offering of common stock and pre-funded warrants to two institutional investors. The offering is intended to raise approximately $7 million in gross proceeds to be used for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: The issuance of over 12 million shares at $0.55 represents a substantial increase in share count for the company.
- Low share price: Pricing at $0.55 is near the threshold often associated with Nasdaq compliance risks and high volatility.
- Pre-funded warrants: Use of pre-funded warrants is a common mechanism used to avoid certain ownership thresholds but can lead to future dilution upon exercise.
📋 Key Facts
- Offering size: 12,002,272 shares at $0.55 per share.
- Warrants: 725,000 pre-funded warrants priced at $0.5499 per warrant with an exercise price of $0.0001.
- Gross proceeds: Approximately $7 million before fees and expenses.
- Placement Agent: Maxim Group LLC (7.0% cash fee plus up to $50,000 in expense reimbursement).
- Expected closing date: October 29, 2025.
- Use of proceeds: Working capital and general corporate purposes.
Co-Diagnostics, Inc. has entered into a new $10 million at-the-market (ATM) equity distribution agreement with Maxim Group LLC to facilitate the sale of common stock. This follows the termination of a previous ATM agreement with Piper Sandler & Co. and Clear Street LLC.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- Frequent changes in ATM providers (terminated previous agreement with Piper Sandler & Co. on Sept 30, 2025).
📋 Key Facts
- Entered into an Equity Distribution Agreement with Maxim Group LLC on October 20, 2025.
- The ATM program allows for the sale of common stock up to an aggregate amount of $10,000,000.
- Maxim Group LLC will act as the sole sales agent with a 3.0% commission on gross sales.
- A prospectus supplement was filed registering up to $4,086,645 of shares related to this offering.
- The company terminated its previous ATM agreement (dated April 25, 2025) effective September 30, 2025.
Co-Diagnostics, Inc. filed an 8-K under Item 7.01 (Regulation FD Disclosure) to incorporate a press release dated September 30, 2025. The filing does not contain substantive financial or structural changes in the provided text.
📋 Key Facts
- Filing date: September 30, 2025
- Item 7.01 (Regulation FD Disclosure) was used to provide information via a press release (Exhibit 99.1)
- Signed by Brian Brown, Chief Financial Officer
Co-Diagnostics, Inc. entered into a securities purchase agreement to conduct a registered direct offering of 9,619,000 shares at $0.40 per share, aiming to raise approximately $3.8 million for working capital.
🚩 Red Flags
- Significant dilution: The offering of ~9.6M shares at $0.40 represents a substantial amount of equity relative to typical micro-cap structures.
- Low share price: Pricing at $0.40 suggests the company may be facing liquidity constraints or navigating Nasdaq minimum bid price requirements.
- Use of proceeds: Funds are earmarked for 'working capital and general corporate purposes,' which often indicates a need to cover operational burn rather than specific growth projects.
📋 Key Facts
- Offering size: 9,619,000 shares of common stock.
- Price per share: $0.40.
- Aggregate gross proceeds: Approximately $3.8 million (before fees).
- Placement Agent: Maxim Group LLC (7.0% cash fee + expenses up to $50,000).
- Investors received participation rights for 30% of subsequent financing within 12 months.
- Expected closing date: September 18, 2025.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal announcement of earnings and includes non-GAAP financial measures in the attached press release.
📋 Key Facts
- Company announced quarterly financial results for the period ending June 30, 2025.
- The announcement was made via press release dated August 14, 2025.
- The filing includes information regarding non-GAAP financial measures in Exhibit 99.1.
Co-Diagnostics, Inc. has received notification from NASDAQ granting an additional 180-day grace period to regain compliance with the $1.00 minimum bid requirement. The company failed to meet the initial grace period and must now address the deficiency by January 5, 2026.
🚩 Red Flags
- Delisting risk: Failure to meet minimum bid requirement.
- Potential for imminent reverse stock split to artificially inflate share price.
- Repeated failure to maintain compliance (failed first 180-day grace period).
📋 Key Facts
- NASDAQ granted an additional 180-day grace period ending January 5, 2026.
- The company failed to regain compliance during the initial 180-day grace period regarding the $1.00 minimum bid requirement.
- Eligibility for the second grace period is based on meeting market value requirements and other listing standards except for the bid price.
- The company has indicated it may effect a reverse stock split to cure the deficiency.
Co-Diagnostics, Inc. held its 2025 annual meeting of shareholders on May 28, 2025. Shareholders successfully elected five directors and approved several key proposals including a new equity incentive plan and executive compensation.
📋 Key Facts
- Annual meeting held on May 28, 2025.
- Five directors (Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson, Eward Murphy) were elected to one-year terms.
- The 2025 Equity Incentive Plan was adopted by shareholders.
- Shareholders approved executive compensation on an advisory basis.
- Ratification of Tanner LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Co-Diagnostics, Inc. issued an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal mechanism to furnish quarterly earnings information and non-GAAP financial measures via a press release.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The company furnished a press release (Exhibit 99.1) containing financial results and non-GAAP measures.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Co-Diagnostics, Inc. has amended its existing equity distribution agreement to add Clear Street LLC as an additional sales agent alongside Piper Sandler & Co. This amendment updates the plan of distribution for the company's ATM (at-the-market) program.
🚩 Red Flags
- Ongoing use of an equity distribution agreement (ATM) indicates a continued need for capital through share dilution.
📋 Key Facts
- Amended and Restated Equity Distribution Agreement entered into on April 25, 2025.
- Clear Street LLC added as a sales agent to the existing agreement with Piper Sandler & Co.
- Sales commissions will be divided equally between Piper Sandler and Clear Street.
- The original aggregate offering price under the agreement is up to $50,000,000.
- As of April 25, 2025, the company has already sold 833,806 shares via this program.
Co-Diagnostics, Inc. issued an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures.
📋 Key Facts
- Reporting date: March 27, 2025
- Period covered: Fiscal year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- Financial results include the use of non-GAAP financial measures.
Co-Diagnostics, Inc. issued an 8-K to provide a regulatory update regarding its FDA 510(k) application for the Co-Dx™ PCR COVID-19 Test on the PCR Pro™ platform.
📋 Key Facts
- The filing is an update concerning a 510(k) application to the FDA.
- The product in question is the Co-Dx™ PCR COVID-19 Test on the PCR Pro™.
- The announcement was made via press release dated February 21, 2025.
Co-Diagnostics, Inc. received a notice from Nasdaq stating its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 9, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Persistent low share price (below $1.00) indicating significant loss of market capitalization or investor confidence
📋 Key Facts
- Received notice on January 10, 2025, regarding a violation of Nasdaq Listing Rule 5550(a)(2).
- The deficiency is due to the closing bid price being below $1.00 for the last 30 consecutive business days.
- Compliance deadline (Compliance Date) is July 9, 2025.
- To regain compliance, the stock must close at $1 or more for at least ten consecutive business days before the deadline.
- The company may be eligible for an additional 180-day second compliance period if it meets market value requirements and intends to effect a reverse stock split.
This is an amendment to a previous 8-K filing regarding the results of the company's 2024 Annual Meeting of Shareholders. The primary purpose is to disclose that shareholders voted in favor of conducting 'Say-on-Pay' advisory votes on an annual basis.
📋 Key Facts
- The filing is an Amendment (8-K/A) to the original report filed on August 30, 2024.
- Shareholders at the August 29, 2024 Annual Meeting voted in favor of conducting advisory Say-on-Pay votes annually.
- The Board of Directors will conduct these votes every year until a new vote regarding frequency is held.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures in the attached exhibit.
📋 Key Facts
- Reporting date: November 7, 2024
- Period covered: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and non-GAAP measures.
- Signed by Brian Brown, Chief Financial Officer.
Co-Diagnostics, Inc. held its 2024 annual meeting of shareholders on August 29, 2024. The filing reports the results of shareholder votes regarding director elections, executive compensation advisory votes, and the ratification of the independent auditor.
📋 Key Facts
- James Nelson was elected to a three-year term as a director with 6,684,070 votes in favor.
- Shareholders approved the non-binding resolution on executive officer compensation (Say-on-Pay) with 9,312,471 votes for and 1,279,949 against.
- Shareholders voted to maintain an annual frequency (One Year) for future advisory votes on executive compensation.
- The appointment of Tanner LLC as the independent registered public accounting firm for the year ending December 31, 2024, was ratified with 13,285,933 votes in favor.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release and includes non-GAAP financial measures.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- The filing includes information regarding the use of non-GAAP financial measures.
Co-Diagnostics, Inc. announced the submission of a 510(k) application to the FDA for its Co-Dx™ PCR Pro™ Platform on June 14, 2024.
📋 Key Facts
- Company submitted a 510(k) Application to the FDA.
- The application is specifically for the Co-Dx™ PCR Pro™ Platform.
- Filing date: June 14, 2024.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024. The filing serves as a formal announcement of earnings and includes non-GAAP financial measures in the attached press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 9, 2024
- The company issued a press release (Exhibit 99.1) containing financial results and non-GAAP measures.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Co-Diagnostics, Inc. announced the appointment of Richard Abbott as President on March 15, 2024. Mr. Abbott previously served as President of Advanced Conceptions, Inc., a subsidiary acquired by the company in December 2021.
🚩 Red Flags
- Related-party transaction potential: Abbott's entity (Whiteknob LLC) has ongoing milestone-based equity incentives tied to the prior acquisition.
📋 Key Facts
- Richard Abbott appointed as President effective March 15, 2024.
- Abbott was previously President of Advanced Conceptions, Inc. (a wholly owned subsidiary) from January 2021 to March 2024.
- Advanced Conceptions was acquired by Co-Diagnostics in December 2021.
- Whiteknob LLC (owned 50% by Abbott) held a 71.61% interest in Advanced Conceptions at the time of acquisition.
- Contingent consideration: Whiteknob LLC may earn an additional 507,386 common shares and 166,503 warrants upon achievement of milestones.
Co-Diagnostics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of earnings and includes non-GAAP financial measures in the attached press release.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing financial results and non-GAAP measures
- Signed by Brian Brown, Chief Financial Officer